Published in the Journal of the American Pharmacists Association, June 11, 2021, Throughout much of 2020 and the beginning of 2021, while coronavirus disease 2019 (COVID-19) continued to grow and spread, government and public health officials worldwide

More than 32 million individuals have survived a confirmed COVID-19 viral infection in the USA [1, 2], and a substantial proportion of post-COVID survivors are suffering from prolonged, recurrent, and/or newly emerging symptoms that span across bodily systems and organs [3]. The spectrum of symptoms and disabilities observed in this setting has been alarming and suggests that the “post-COVID syndrome” is a pan-inflammatory disease with highly variable disease expression and consequences [4]. However, accurately and completely characterizing post-COVID syndrome is difficult because many individuals with acute COVID-19 infection were not hospitalized, and therefore were not tracked through standard, in-patient-based data reporting mechanisms to public health authorities [5].

Published on Cancer Commons, June 29, 2021, Curious Dr. George asks two leaders from the Reagan-Udall Foundation for the Food and Drug Administration (FDA) how their organization supports the FDA by striving to facilitate patient access to investigational products.

The Reagan-Udall Foundation’s Evidence Accelerator program is navigating novel data flow challenges when it comes to assessing the safety and effectiveness of COVID-19 vaccines. The Evidence Accelerator was launched in April 2020 by Reagan-Udall, a foundation that supports the US Food and Drug Administration, and Friends of Cancer Research to identify key questions about the COVD-19 pandemic that could be addressed through real-world data and real-world evidence and pressure-testing approaches to address those questions.

Mothers are particularly hesitant about getting the COVID-19 vaccine for themselves and their children, according to the latest data.